Beam Therapeutics Inc.

BEAMNASDAQHealthcare● Active

$29.78

+$0.38(+1.29%)

Market Cap$3.1B

P/E Ratio—

52W High$36.44

52W Low$15.6

Avg Volume2.0M

Open$29.95

Beta2.20

Free Cash Flow Financials Revenue

Beam Therapeutics Inc. (BEAM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BEAM · free cash flow · updated Jun 9, 2026

Core FCF metrics

BEAM · FCF · TTM · margin & CAGR

Free cash flow was −$360.0M for FY2025 (fiscal year ending 2025-12-31), down 1.1% year-over-year The FCF margin was -257.6%.

FY2025 Free Cash Flow−$360.0M▼ -1.1% YoY

Trailing 12M (TTM)−$383.8Mtrailing 4 quarters sum

FCF Margin-257.6%−$360.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BEAM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$345.1M(15M)−$360.0M▼ 1.1%-257.6%

FY2024−$347.2M(9M)−$356.2M▼ 94.7%-560.8%

FY2023−$149.2M(34M)−$182.9M▼ 592.3%-48.4%

FY2022$22.5M(49M)−$26.4M▲ +76.6%-43.4%

FY2021−$66.3M(47M)−$113.1M▼ 0.9%-218.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BEAM · P/FCF · FCF yield · FCF per share

Beam Therapeutics Inc. (BEAM) reported negative free cash flow of −$0.36B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BEAM · cash flow statement · operating / investing / financing

For FY2025, Beam Therapeutics Inc. generated −$345.1M in operating cash flow and spent 15M in capital expenditures, yielding −$360.0M in free cash flow.

Operating Activities

−$345.1M

Cash from core business operations

2025-12-31

Investing Activities

−$121.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$478.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$345.1M) − |CapEx| (15M) = FCF (−$360.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BEAM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Beam Therapeutics Inc.YOU

BEAM

−$360.0M-1.1%-257.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Beam Therapeutics Inc. (BEAM) reported free cash flow of −$360.0M for FY2025 (fiscal year ending 2025-12-31), down 1.1% year-over-year. The FCF margin was -257.6%.

Beam Therapeutics Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BEAM free cash flow · 8 questions

Beam Therapeutics Inc. free cash flow was −$360.0M for FY2025, down 1.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$383.8M.

BEAM free cash flowBEAM FCFBEAM FCF 2025BEAM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Beam Therapeutics Inc. · Beam Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026